Market closedNon-fractional
CareDx/CDNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About CareDx
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
Ticker
CDNA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
639
Website
caredx.com
CareDx Metrics
BasicAdvanced
$985M
Market cap
-
P/E ratio
-$3.44
EPS
1.77
Beta
-
Dividend rate
Price and volume
Market cap
$985M
Beta
1.77
Financial strength
Current ratio
4.317
Quick ratio
3.932
Long term debt to equity
10.496
Total debt to equity
12.859
Management effectiveness
Return on assets (TTM)
-12.63%
Return on equity (TTM)
-54.18%
Valuation
Price to revenue (TTM)
3.654
Price to book
3.83
Price to tangible book (TTM)
5.68
Price to free cash flow (TTM)
-23.752
Growth
Revenue change (TTM)
-13.93%
Earnings per share change (TTM)
127.76%
3-year revenue growth (CAGR)
7.54%
3-year earnings per share growth (CAGR)
130.87%
What the Analysts think about CareDx
Analyst Ratings
Majority rating from 7 analysts.
CareDx Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$72M
9.92%
Net income
-$17M
-85.93%
Profit margin
-23.05%
-87.21%
CareDx Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.18
-$0.18
-$0.17
-$0.03
-
Expected
-$0.31
-$0.40
-$0.27
-$0.21
-$0.15
Surprise
-41.94%
-54.48%
-36.19%
-85.44%
-
CareDx News
AllArticlesVideos
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CareDx, Inc. (NASDAQ: CDNA)
PRNewsWire·1 week ago
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
Business Wire·2 months ago
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CareDx stock?
CareDx (CDNA) has a market cap of $985M as of July 27, 2024.
What is the P/E ratio for CareDx stock?
The price to earnings (P/E) ratio for CareDx (CDNA) stock is 0 as of July 27, 2024.
Does CareDx stock pay dividends?
No, CareDx (CDNA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next CareDx dividend payment date?
CareDx (CDNA) stock does not pay dividends to its shareholders.
What is the beta indicator for CareDx?
CareDx (CDNA) has a beta rating of 1.77. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell CareDx stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.